Eculizumab in paroxysmal nocturnal hemoglobinuria [2]

New England Journal of Medicine

Volumn 355, Issue 26, 2006, Pages 2786-

  Singh, Jaswinder ^a   Malani, Ashok K ^b   Pabla, Maninder ^b  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^b Heartland Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ECULIZUMAB; GLYCOSYLPHOSPHATIDYLINOSITOL; MONOCLONAL ANTIBODY;

BLOOD TRANSFUSION; ERYTHROCYTE; ETHNICITY; GRANULOCYTE; HIGH RISK POPULATION; HUMAN; LETTER; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK ASSESSMENT; CHEMISTRY; ETHNOLOGY; FEMALE; METHODOLOGY; NOTE; PREGNANCY;

ANTIBODIES, MONOCLONAL; FEMALE; GLYCOSYLPHOSPHATIDYLINOSITOLS; GRANULOCYTES; HEMOGLOBINURIA, PAROXYSMAL; HUMANS; PREGNANCY; RESEARCH DESIGN;

EID: 33845881214     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc062885     Document Type: Letter

References (4)

1. Rosse WF. The life-span of complement-sensitive and -insensitive red cells in paroxysmal nocturnal hemoglobinuria. Blood 1971;37:556-62.
2. Brubaker LH, Essig LJ, Mengel CE. Neutrophil life span in paroxysmal nocturnal hemoglobinuria. Blood 1977;50:657-62.
3. Araten DJ, Thaler HT, Luzzatto L. High incidence of thrombosis in African-American and Latin-American patients with paroxysmal nocturnal haemoglobinuria. Thromb Haemost 2005;93:88-91.
4. Tichelli A, Socie G, Marsh J, et al. Outcome of pregnancy and disease course among women with aplastic anemia treated with immunosuppression. Ann Intern Med 2002;137:164-72.